Loading...
Market
What will be the primary outcome of Neuralink's CAN-PRIME trial by end of 2025?
2
Resolution / Starting Odds
Positive outcome • 25%
Negative outcome • 25%
Inconclusive outcome • 25%
Trial not completed • 25%
Neuralink's official trial results or peer-reviewed journals
Story
Neuralink Secures Health Canada Approval for CAN-PRIME Trial at Toronto Western Hospital to Test N1 Implant on Six Paralysis Patients
Nov 25, 2024, 06:22 PM
Neuralink, the brain-computer interface company founded by Elon Musk, has received approval from Health Canada to conduct its first trial in Canada, named CAN-PRIME. The trial will recruit six participants suffering from severe paralysis due to amyotrophic lateral sclerosis (ALS) or spinal cord injuries. This study will be held at Toronto Western Hospital and aims to evaluate the safety and effectiveness of the N1 Implant, which is designed to extend brain-computer interface (BCI) control to an investigational assistive robotic arm. Neuralink's announcement emphasizes the significance of this trial as a crucial step towards restoring both digital and physical autonomy for individuals with paralysis.
View original story
Similar markets
Full success • 25%
Partial success • 25%
No success • 25%
Trial discontinued • 25%
Successful with no issues • 25%
Successful with minor issues • 25%
Unsuccessful • 25%
Trial halted • 25%
Significant improvement in mobility • 25%
Moderate improvement in mobility • 25%
No improvement in mobility • 25%
Trial inconclusive • 25%
Successful with significant findings • 25%
Successful with limited findings • 25%
Unsuccessful • 25%
Indeterminate • 25%
Recruitment completion • 25%
Initial results published • 25%
Trial expansion approved • 25%
Trial discontinued • 25%
Restoration of hand movement • 25%
Restoration of leg movement • 25%
Improvement in speech • 25%
Other • 25%
Achieves full sensory feedback • 25%
Enables multi-device control • 25%
Significant AI integration • 25%
Other • 25%
Very Positive • 25%
Somewhat Positive • 25%
Neutral • 25%
Negative • 25%
Significant improvement • 25%
Moderate improvement • 25%
No significant improvement • 25%
Worsening of symptoms • 25%
Assistive technology for paralysis • 25%
Cognitive enhancement • 25%
Medical treatment for neurological disorders • 25%
Other • 25%
New regulatory approval • 25%
New patient milestone • 25%
Commercial availability plans • 25%
New technological breakthrough • 25%